الفهرس | Only 14 pages are availabe for public view |
Abstract Purpose: The aim of current study is to assess the effect of cabergoline, one of dopamine agonists on glycemic control, lipid profile, liver functions, dopamine levels and cardiovascular biomarker, hsCRP on type 2 diabetic patients. Methods: This prospective randomized parallel study involved fifty diabetic patients who were divided into two groups. The first group received gliclazide (60-120 mg) once daily. The second group received cabergoline 0.5 mg twice weekly plus gliclazide (60-120 mg) once daily. Fasting plasma glucose, postprandial plasma glucose, glycated haemoglobin (HbA1c), fasting insulin, Homeostatic model assessment of insulin resistance (HOMA-IR), lipid profile (total cholesterol, low density lipoproteins (LDL) cholesterol, high density lipoproteins (HDL) cholesterol, triglycerides), liver function tests (aspartate transaminase (AST), alanine transaminase (ALT)), dopamine levels, and high sensitive C-reactive protein were measured at baseline and after 4 months of treatment. Fasting plasma glucose and postprandial plasma glucose were measured every month. Results: Treatment of the patients with cabergoline and gliclazide resulted in greater significant (p<0.05) decrease in FBG, PPBG, HbA1c compared to treatment with gliclazide only and insignificant (p<0.05) change in ALT and AST compared to pretreatment normal levels. group 2 diabetic patients exhibit a significant decrease in (p<0.05) hsCRP compared to pretreatment levels and a significant increase (p<0.05) in dopamine levels after four months of cabergoline treatment. Conclusion: Cabergoline improved glycemic control via resetting dopaminergic and noradrenergic tone in ventromedial hypothalamus. Insulin levels were reduced and insulin sensitivity was enhanced with improvement in lipid profile. Suppression of insulin secretion induces β-cell rest, increases the number of organ-specific insulin receptors and improves insulin sensitivity. Cabergoline maintains liver functions (ALT and AST levels) and reduces hsCRP levels to offer a new promising antidiabetic drug with unique insulin sensitizing actions and accepted hepatic and cardiovascular safety profile for type 2 diabetic patients. |